News
Glaucoma is one of the world’s leading causes of irreversible blindness, and currently, no therapies exist to directly protect retinal ganglion cells (RGC) from degradation and loss. NIH inventors have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal
1 in every 200 people with eye-related irritation in the US has uveitis. Vision loss can occur if the uveitis remains untreated, therefore, early detection is crucial. Certain uveitis cases currently require fluorescein angiography (FA) for diagnosis due to its ability to display retinal vascular
Current diagnostic tests for COVID-19 and other viruses require RNA extraction and analysis of the extracted RNA sample. NIH Inventors have developed a novel, improved sample preparation method that eliminates the need for an RNA extraction step. The inventors discovered that incorporating a
NIH inventors have developed the first known method of producing Regulatory B-cells (Bregs) ex-vivo. There is a great need to supplement the low population of Bregs in a patient suffering from an autoimmune disease where Breg levels are severely reduced, such as uveitis. This method involves